Chapter 52: Managing Breast Disorders

Managing Breast Disorders nursing chapter details the professional assessment and management of patients experiencing both benign and malignant breast disorders, starting with an essential review of breast anatomy and physiology, including the Tanner stages of development and key structures like the Tail of Spence and Cooper ligaments. Patient assessment protocols emphasize a targeted health history and physical examination, covering female and male breast exams, focused inspection for potential malignancy indicators such as skin thickening (peau d’orange), venous patterns, and nipple changes, along with systematic palpation for masses and evaluation of axillary lymph nodes. Early detection and diagnostic methods are thoroughly reviewed, promoting breast self-awareness and education. These methods include various forms of mammography (digital and 3D), ultrasonography to distinguish cysts from solid lesions, and Magnetic Resonance Imaging (MRI), particularly recommended for high-risk women. Confirmation of pathology requires tissue analysis via biopsy, which may be percutaneous (such as fine-needle aspiration or computer-guided stereotactic core biopsy) or surgical (excisional, incisional, or wire needle localization). A dedicated section addresses various benign conditions like mastalgia (breast pain), fibrocystic changes, mastitis, and benign proliferative breast diseases, including atypical hyperplasia and lobular carcinoma in situ (LCIS), which necessitate increased surveillance due to elevated cancer risk. The chapter provides an extensive overview of malignant conditions (breast cancer), reviewing critical risk factors such as increasing age, obesity, and hereditary mutations in the BRCA1 and BRCA2 genes. Specific cancer types range from noninvasive Ductal Carcinoma in situ (DCIS), classified as stage 0, to various invasive carcinomas like infiltrating ductal and inflammatory carcinoma. Prognosis is determined by factors including tumor size, staging (TNM classification), and biological markers such as hormone receptor status (ER/PR) and HER-2/neu protein expression. Treatment options aim for local control through surgery, encompassing breast conservation treatment (lumpectomy) often followed by radiation therapy, or various forms of mastectomy. A crucial component is lymph node staging, contrasting the low-morbidity Sentinel Lymph Node Biopsy (SLNB) with the more extensive Axillary Lymph Node Dissection (ALND). Systemic therapies discussed include adjuvant chemotherapy, often employing dose-dense regimens, hormonal therapy (using agents like tamoxifen or aromatase inhibitors) for hormone receptor-positive disease, and targeted therapy agents like Trastuzumab. Throughout the process, the nursing role is highlighted, focusing on managing anxiety and pain, patient education (including drain care and arm exercises), promoting coping, managing postoperative sensations, and monitoring for potential complications such as lymphedema, seroma, and infection. Special considerations include breast reconstructive procedures (tissue expanders, TRAM flap), genetic counseling implications, and long-term survivorship care.